GlassScriptPhysician profile
Rakesh C Gupta
NPI 1871574996
$2,025.09
in general payments reported to CMS, 2019-2025
25 companies · $430 in 2025
The $430 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $96.95 · 2021: $194 · 2022: $214 · 2023: $337 · 2024: $576 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $317.03 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $236.57 | 2021-2025 | |
| Abbvie INC. | $196.07 | 2021-2025 | |
| Lilly USA, LLC | $180.92 | 2020-2025 | Mounjaro, Emgality, Jardiance |
| Shionogi INC | $148.39 | 2023-2025 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.99 | 2019-2024 | Spiriva Respimat |
| Glaxosmithkline, LLC. | $107.44 | 2019-2023 | Nucala |
| Shield Therapeutics INC | $83.15 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $71.54 | 2020-2022 | |
| Medtronic, INC. | $69.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $66.76 | 2024-2025 | Dupixent |
| Harmony Biosciences LLC | $61.08 | 2024 | |
| Merck Sharp & Dohme LLC | $57.98 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Sunovion Pharmaceuticals INC. | $49.11 | 2019 | |
| Genzyme Corporation | $39.06 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.82 | 2019-2020 | |
| Ardelyx, INC. | $26.00 | 2025 | Ibsrela |
| Grifols USA, LLC | $25.19 | 2024 | Prolastin-C Liquid |
| Viatris Specialty LLC | $22.48 | 2025 | Yupelri |
| Baxter Healthcare | $22.43 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Idorsia Pharmaceuticals US INC | $19.84 | 2023 | Quviviq |
| Novo Nordisk INC | $18.99 | 2024 | Wegovy |
| Alkermes, INC. | $15.93 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.84 | 2025 | Caplyta |
| Sun Pharmaceutical Industries INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.